Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Xentuzumab, an antibody targeting IGF1 and IGF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Diridavumab, an antibody targeting Influenza A HA2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emibetuzumab, an antibody targeting MET.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Navicixizumab, an antibody targeting DLL4 × VEGF-A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Plozalizumab, an antibody targeting CCR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Trevogrumab, an antibody targeting MSTN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cabiralizumab, an antibody targeting CSF1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Utomilumab, an antibody targeting 4-1BB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Naratuximab, an antibody targeting CD37.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tomuzotuximab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ifabotuzumab, an antibody targeting EPHA3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Larcaviximab, an antibody targeting Zaire Ebolavirus Glycoprotein.